INTRODUCTION: YKL-40 is a novel biomarker in diseases with inflammation, fibrosis and tissue remodelling. Previously, circulating YKL-40 was shown to be elevated in patients with idiopathic pulmonary fibrosis (IPF) and was associated with survival. OBJECTIVE: To compare YKL-40 serum levels between IPF and other interstitial pneumonias such as non-specific interstitial pneumonia (NSIP), smoking-related interstitial lung disease (SR-ILD) and cryptogenic organising pneumonia (COP). MATERIALS AND METHODS: Serum YKL-40 levels were measured in 124 healthy controls and 315 patients. Serial measurements were available in 36 patients with IPF and 6 patients with COP. RESULTS: Serum YKL-40 levels were elevated in all patient groups compared to controls (p < 0.0001), and highest levels were found in the most fibrotic diseases, which showed worst prognosis. CONCLUSION: YKL-40 is highly elevated in fibrotic interstitial pneumonias and may reflect the degree of activity of the fibrogenic process. Remarkably, levels remain high in IPF, but can decrease in other interstitial pneumonias, which appears to be related to a better prognosis.
INTRODUCTION:YKL-40 is a novel biomarker in diseases with inflammation, fibrosis and tissue remodelling. Previously, circulating YKL-40 was shown to be elevated in patients with idiopathic pulmonary fibrosis (IPF) and was associated with survival. OBJECTIVE: To compare YKL-40 serum levels between IPF and other interstitial pneumonias such as non-specific interstitial pneumonia (NSIP), smoking-related interstitial lung disease (SR-ILD) and cryptogenic organising pneumonia (COP). MATERIALS AND METHODS: Serum YKL-40 levels were measured in 124 healthy controls and 315 patients. Serial measurements were available in 36 patients with IPF and 6 patients with COP. RESULTS: Serum YKL-40 levels were elevated in all patient groups compared to controls (p < 0.0001), and highest levels were found in the most fibrotic diseases, which showed worst prognosis. CONCLUSION:YKL-40 is highly elevated in fibrotic interstitial pneumonias and may reflect the degree of activity of the fibrogenic process. Remarkably, levels remain high in IPF, but can decrease in other interstitial pneumonias, which appears to be related to a better prognosis.
Authors: Dmitri V Pechkovsky; Antje Prasse; Florian Kollert; Kathrin M Y Engel; Jan Dentler; Werner Luttmann; Karlheinz Friedrich; Joachim Müller-Quernheim; Gernot Zissel Journal: Clin Immunol Date: 2010-07-31 Impact factor: 3.969
Authors: Nicoline M Korthagen; Coline H M van Moorsel; Nicole P Barlo; Henk J T Ruven; Adrian Kruit; Michiel Heron; Jules M M van den Bosch; Jan C Grutters Journal: Respir Med Date: 2011-01 Impact factor: 3.415
Authors: B Volck; P A Price; J S Johansen; O Sørensen; T L Benfield; H J Nielsen; J Calafat; N Borregaard Journal: Proc Assoc Am Physicians Date: 1998 Jul-Aug
Authors: Sebastian Majewski; Damian Tworek; Karolina Szewczyk; Justyna Kiszałkiewicz; Zofia Kurmanowska; Ewa Brzeziańska-Lasota; Hanna Jerczyńska; Adam Antczak; Wojciech Jerzy Piotrowski; Paweł Górski Journal: Int J Chron Obstruct Pulmon Dis Date: 2019-07-22
Authors: Nikhil Hirani; Alison C MacKinnon; Lisa Nicol; Paul Ford; Hans Schambye; Anders Pedersen; Ulf J Nilsson; Hakon Leffler; Tariq Sethi; Susan Tantawi; Lise Gravelle; Robert J Slack; Ross Mills; Utsa Karmakar; Duncan Humphries; Fredrik Zetterberg; Lucy Keeling; Lyn Paul; Philip L Molyneaux; Feng Li; Wendy Funston; Ian A Forrest; A John Simpson; Michael A Gibbons; Toby M Maher Journal: Eur Respir J Date: 2021-05-27 Impact factor: 16.671